Neurocrine Biosciences (NBIX) Depreciation & Amortization (CF) (2010 - 2026)

Neurocrine Biosciences' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 9.09% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (up 7.26% YoY) and the FY2025 annual result came in at $26.0 million, up 10.64% from the prior year.
• Depreciation & Amortization (CF) was $7.2 million for Q1 2026 at Neurocrine Biosciences, up from $6.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $7.2 million in Q1 2026 and bottomed at $3.3 million in Q1 2022.
• A 5-year average of $5.3 million and a median of $5.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) surged 52.38% — and 2025, when it retreated 1.56%.
• Neurocrine Biosciences' Depreciation & Amortization (CF) stood at $3.9 million in 2022, then gained by 25.64% to $4.9 million in 2023, then gained by 26.53% to $6.2 million in 2024, then grew by 3.23% to $6.4 million in 2025, then gained by 12.5% to $7.2 million in 2026.
• Business Quant data shows NBIX's Depreciation & Amortization (CF) at $7.2 million in Q1 2026, $6.4 million in Q4 2025, and $6.7 million in Q3 2025.